NCT05064319View on ClinicalTrials.gov

Gabapentin for Restoring GABA/Glutamate Homeostasis in Co-occurring Bipolar and Cannabis Use Disorders

PHASE2RecruitingINTERVENTIONAL
Enrollment

68

Participants

Timeline

Start Date

February 24, 2022

Primary Completion Date

June 30, 2026

Study Completion Date

June 30, 2026

Conditions
Bipolar DisorderCannabis UseSchizoaffective Disorder, Bipolar TypeBipolar I DisorderBipolar II DisorderCannabis Use Disorder, MildCannabis Use Disorder, ModerateCannabis Use Disorder, Severe
Interventions
DRUG

Gabapentin

After group assignment but before taking any study medication, and again 17 days later, participants will have a Magnetic Resonance Imaging (MRI) exam after completing various assessments (clinical interview, questionnaires, etc.). Group A will receive gabapentin 2-3 times a day for a total of 17 days.

DRUG

Placebo

After group assignment but before taking any study medication, and again 17 days later, participants will have a Magnetic Resonance Imaging (MRI) exam after completing various assessments (clinical interview, questionnaires, etc.). Group A will receive placebo 2-3 times a day for a total of 17 days.

Trial Locations (1)

29425

RECRUITING

Medical University Of South Carolina, Charleston

All Listed Sponsors
collaborator

National Institute on Drug Abuse (NIDA)

NIH

lead

Medical University of South Carolina

OTHER